Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
52,443
Total Claims
$11.9M
Drug Cost
713
Beneficiaries
$17K
Cost/Patient
Risk Score Breakdown 38/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-81%
Opioid rate vs peers
0.4% vs 2.2% avg
+1085%
Cost per patient vs peers
$17K vs $1,411 avg
+79%
Brand preference vs peers
19.0% vs 10.6% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Cost per patient is 1085% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.4%
Opioid Rate
224
Opioid Claims
$2,365
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 9,909 claims · $7.1M
Generic: 42,123 claims · $4.8M
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Metformin Hcl | 530 | $1.4M |
| Diclofenac Sodium | 1,153 | $772K |
| Semaglutide | 735 | $755K |
| Omeprazole/Sodium Bicarbonate | 329 | $735K |
| Somatropin | 18 | $560K |
| Lipase/Protease/Amylase | 417 | $501K |
| Linaclotide | 613 | $344K |
| Dulaglutide | 301 | $328K |
| Apixaban | 427 | $287K |
| Sacubitril/Valsartan | 364 | $265K |
| Empagliflozin | 387 | $248K |
| Dapagliflozin Propanediol | 384 | $244K |
| Fluticasone/Umeclidin/Vilanter | 304 | $219K |
| Dihydroergotamine Mesylate | 56 | $176K |
| Icosapent Ethyl | 420 | $158K |
Prescribing Profile
Patient Profile
77
Avg Age
59%
Female
1.75
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About